Good morning :)
$
₹
Illumina Inc

Illumina Inc

ILMN

NASDAQ
Asset Logo

Illumina Inc

ILMN

NASDAQ
$226.684.84% (-11.53)
$
₹
$226.684.84% (-11.53)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Diagnostics & Research

Large Cap

With a market cap of $34.3B the stock is ranked 442

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

38.99
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

11.34
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$5.81
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

2.91
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

19.72%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 21 analysts reports

Buy
10 analysts
Hold
7 analysts
Sell
4 analysts

Price Upside

+9.82%

Earnings Growth

+12.62%

Rev. Growth

+6.79%

See Detailed Forecast

Company Profile

Company Profile

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
P/E Ratio
36.00
36.00
1Y Return
24.93%
24.93%
Buy Reco %
85.18
85.18
Agilent Technologies Inc
A
Agilent Technologies Inc
P/E Ratio
34.46
34.46
1Y Return
20.11%
20.11%
Buy Reco %
68.18
68.18
Waters Corporation
WAT
Waters Corporation
P/E Ratio
113.80
113.80
1Y Return
27.29%
27.29%
Buy Reco %
78.26
78.26
IQVIA Holdings Inc
IQV
IQVIA Holdings Inc
P/E Ratio
31.29
31.29
1Y Return
25.04%
25.04%
Buy Reco %
90.00
90.00
Mettler-Toledo International Inc
MTD
Mettler-Toledo International Inc
P/E Ratio
37.82
37.82
1Y Return
21.32%
21.32%
Buy Reco %
38.46
38.46
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 9.82% growth, versus a trailing 3-year CAGR of 29.47%.

2026
Current$238.21Baseline
Analyst Target - 1 year
Target$261.6+9.82%

All values in $

202220232024202520262027$160.47$202.90$245.33Target+9.82%
2026
Current$238.21Baseline
Analyst Target - 1 year
Target$261.6+9.82%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 6.79% growth, versus a trailing 3-year CAGR of -1.82%.

2025
Current$4.33Baseline
Forecast for Dec 2026
High$4.65+7.26%
Average$4.63+6.79%
Low$4.59+6.03%

All values in $ Billion

2021202220232024202520264.524.584.504.374.33Low+6.03%Average+6.79%High+7.26%
2025
Current$4.33Baseline
Forecast for Dec 2026
High$4.65+7.26%
Average$4.63+6.79%
Low$4.59+6.03%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

Lower earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 12.62% growth, versus a trailing 3-year CAGR of 31.77%.

2025
Current$4.85Baseline
Forecast for Dec 2026
High$5.64+16.28%
Average$5.46+12.62%
Low$5.35+10.31%

All values in $

2021202220232024202520265.962.120.872.454.85Low+10.31%Average+12.62%High+16.28%
2025
Current$4.85Baseline
Forecast for Dec 2026
High$5.64+16.28%
Average$5.46+12.62%
Low$5.35+10.31%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

1.1
0.3
1
0.1
1.1
0.2
1.1
0.2
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue1.111.081.101.041.051.081.161.091.151.12
Net Income-1.980.700.180.130.230.150.330.130.200.22
Net Profit Margin-178.77%65.27%16.93%12.58%22.23%13.85%28.79%12.28%17.86%19.48%
See CostsAll values in $ Billion

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDiagnostics & Research

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Illumina Inc 38.9911.342.91
Thermo Fisher Scientific Inc36.004.712.03
Agilent Technologies Inc34.466.691.48
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare ILMN with any stock or ETF
Compare ILMN with any stock or ETF
Comparing from
ILMN
TMO
A
Loading...

Frequently asked questions

  1. Illumina Inc (ILMN) share price today is $226.68 as of November 5, 2026 at 2:29 AM IST. The stock touched a day high of $242.77 and a day low of $224.75.

  2. Illumina Inc stock trades on NASDAQ under the ticker symbol ILMN.

  3. Illumina Inc's market capitalization is $34.25B as of November 5, 2026 at 2:29 AM IST.

  4. Illumina Inc's price-to-earnings (P/E) ratio is 38.99 as of November 4, 2026.

  5. Illumina Inc's price-to-book (P/B) ratio is 11.34 as of November 4, 2026.

  6. Yes, You can buy Illumina Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Illumina Inc shares in three steps: 1. Search Illumina Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Illumina Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Illumina Inc (ILMN) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0441 shares at the current price of $226.68.

Loading...